Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 7/20 | 0.69 |
| ▸ | RAB9A | P51151 | 7/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.62 |
| ▸ | MEN1 | O00255 | 4/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.62 |
| ▸ | HPGD | P15428 | 1/20 | 0.56 |
| ▸ | KCNK3 | O14649 | 5/20 | 0.56 |
| ▸ | KCNK9 | Q9NPC2 | 4/20 | 0.56 |
| ▸ | PKM | P14618 | 1/20 | 0.54 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.51 |
| ▸ | SMO | Q99835 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20522825 | 0.88 | NPC1 (0.73) | NPC1RAB9AKMT2AMEN1SMN1; SMN2 | |
| SCHEMBL20523146 | 0.85 | KCNQ3 (0.62) | NPC1RAB9AKMT2AMEN1SMN1; SMN2 | |
| SCHEMBL30740001 | 0.84 | NPC1 (0.68) | NPC1RAB9AKMT2AMEN1SMN1; SMN2 | |
| SCHEMBL20522767 | 0.82 | RAB9A (0.66) | NPC1RAB9AKMT2AMEN1SMN1; SMN2 | |
| SCHEMBL8203978 | 0.82 | RAB9A (1.00) | NPC1RAB9AKMT2AMEN1SMN1; SMN2 | |
| SCHEMBL6853295 | 0.82 | KMT2A (0.66) | NPC1RAB9AKMT2AMEN1SMN1; SMN2 | |
| SCHEMBL27474740 | 0.78 | NPC1 (0.73) | NPC1RAB9AKMT2AMEN1SMN1; SMN2 | |
| SCHEMBL30456589 | 0.78 | NPC1 (0.77) | NPC1RAB9AKMT2AMEN1SMN1; SMN2 | |
| SCHEMBL28932427 | 0.78 | SMN1; SMN2 (0.65) | NPC1RAB9AKMT2AMEN1SMN1; SMN2 | |
| SCHEMBL4241801 | 0.78 | NPC1 (0.68) | NPC1RAB9AKMT2AMEN1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11345676-B2 | Apoptosis signal-regulating kinase 1 (ASK 1) inhibitor compounds | PHARMAKEA, INC. (US) | 2022-05-31 | — | — | US | disclosed |
| US-11345676-B2 | Apoptosis signal-regulating kinase 1 (ASK 1) inhibitor compounds | PHARMAKEA, INC. (US) | 2022-05-31 | — | — | US | disclosed |
| US-20200048218-A1 | APOPTOSIS SIGNAL-REGULATING KINASE 1 (ASK 1) INHIBITOR COMPOUNDS | PHARMAKEA, INC. | 2020-02-13 | — | — | US | disclosed |
| US-20200048218-A1 | APOPTOSIS SIGNAL-REGULATING KINASE 1 (ASK 1) INHIBITOR COMPOUNDS | PHARMAKEA, INC. | 2020-02-13 | — | — | US | disclosed |
| EP-3601250-A1 | APOPTOSIS SIGNAL-REGULATING KINASE 1 (ASK 1) INHIBITOR COMPOUNDS | Pharmakea, Inc. (US) | 2020-02-05 | — | — | EP | disclosed |
| WO-2018183122-A1 | APOPTOSIS SIGNAL-REGULATING KINASE 1 (ASK 1) INHIBITOR COMPOUNDS | SIDECAR THERAPEUTICS, INC. (US) | 2018-10-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200048218-A1 | APOPTOSIS SIGNAL-REGULATING KINASE 1 (ASK 1) INHIBITOR COMPOUNDS | BAX, BAD, BCL2 | NPC1 1497/4885RAB9A 3670/4885KMT2A 3757/4885 |
| US-11345676-B2 | Apoptosis signal-regulating kinase 1 (ASK 1) inhibitor compounds | BAX, BAD, BCL2 | NPC1 1497/4885RAB9A 3670/4885KMT2A 3757/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.